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Abstract The rat growth hormone (GH) promoter was
significantly activated in non-pituitary cells by the expression
of unliganded trioodothyronine (T3) and retinoic acid (RA)
receptors. Furthermore, a strong ligand-dependent activation was
found in the presence of the pituitary-specific transcription factor
GHF-1. When compared with GHF-1, the splice variant GHF-2
showed a decreased ability to bind the cognate site in the GH
promoter. As a consequence, expression of GHF-2 had little
stimulatory effect on the GH promoter and did not show
cooperation with T3 or RA receptors even in the presence of
ligands. Furthermore, over-expression of GHF-2 inhibited the
response to T3 and RA in pituitary cells. These results show that
alternative splicing of the GHF-1 gene gives rise to two isoforms
that differ in their transactivating properties and in their ability
to synergize with the nuclear thyroid hormone and retinoic acid
receptors on GH gene expression.
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1. Introduction
The pituitary-speci¢c transcription factor GHF-1 (also
called Pit-1) is a member of the homeobox POU family of
DNA-binding proteins [1,2]. Binding of GHF-1 to two se-
quences (365/395 and 3107/3137 base pairs) in the rat
growth hormone (GH) promoter is required for the expression
of this gene in the somatotrophs [3,4].
Di¡erential splicing of the GHF-1 primary transcript gives
rise to a functionally distinct isoform called either GHF-2 [5],
Pit-1b [6] or Pit-1a [7] in prolactin and GH-producing cells. In
GHF-2, 26 additional amino acids are inserted into the acti-
vation domain of the protein. It has been described that this
insertion alters the properties of the transcription factor so
that GHF-2 can activate the GH promoter but cannot acti-
vate the prolactin and GHF-1 promoters [5,7].
Rat GH gene transcription is known to be stimulated by
triiodothyronine (T3) and retinoic acid (RA) [8^11]. A com-
mon responsive element located close to the distal GHF-1
binding site (at 3170/3190) mediates regulation of the rat
GH promoter by T3 and RA receptors (TR and RAR) [12].
Our laboratory and others have shown that the retinoid X
receptor RXR, which heterodimerizes with TR and RAR,
enhances transactivation of the rat GH gene by T3 and RA
[12,13].
In this report we show that T3 and RA receptors produce
both a ligand-dependent and a ligand-independent activation
of the rat GH promoter. These receptors activate the pro-
moter in the absence of GHF-1, and act synergistically with
the pituitary-speci¢c factor. However, GHF-2 binds DNA
with a lower a⁄nity than GHF-1, and as a consequence
shows a markedly decreased ability to transactivate the rat
GH promoter and does not cooperate with the nuclear recep-
tors.
2. Materials and methods
2.1. Plasmids
GH-CAT constructs containing 3530 and 3145 bp of the rat GH
promoter have been described [10]. The plasmid -3000Prl-CAT con-
tains the 5P-£anking sequences of the rat prolactin promoter. Expres-
sion vectors for the rat GHF-1 and GHF-2, the chick TR c-erbAK ,
the human RARK, and the human RXRK have been described pre-
viously [5,14^16].
2.2. Transfections
GH4C1 cells were transfected by electroporation, and Cos-7 and
HeLa cells were transfected with calcium phosphate as previously
described [12,17]. The cells from each transfection were split into
di¡erent culture plates in Dulbecco’s modi¢ed Eagle’s medium con-
taining 10% AG1U8 resin-charcoal stripped newborn calf serum and
treatments with RA and T3 were administered in this hormone-de-
pleted medium. CAT activity was determined by incubation of the cell
extracts with [14C]chloramphenicol as previously described [12,17].
Each experiment was repeated at least two or three times with similar
relative di¡erences in regulated expression.
2.3. Protein preparations
The coding regions of GHF-1 and GHF-2 cloned in Bluescript
SK3, and the vectors for TR, RAR, and RXR cloned in pSG5
were used for in vitro transcription and translation. For this purpose
1 Wg of the di¡erent vectors was transcribed and translated using the
TNT kit (Promega) following the manufacturer’s recommendations.
All reactions were split into two aliquots, one was translated in the
presence of 4 WCi of [35S]methionine (Amersham), and the other in the
presence of the same amount of the unlabeled amino acid. Three Wl of
the reaction product were resolved in 10% sodium dodecyl sulphate-
polyacrylamide (SDS-PAGE) gel electrophoresis. The gel was dried
and autoradiographed overnight. Recombinant GHF-1 and GHF-2
proteins expressed in the bacterial strain BL21(DE3) were also used
[5]. An aliquot of the bacterial extracts used in the DNA binding
studies, run in SDS-PAGE gels and stained with Coomassie blue, is
shown in Fig. 2D.
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2.4. Western blot analysis
Extracts from HeLa cells were run in parallel with GH3 pituitary
cell extracts, and with recombinant GHF-1 or GHF-2 in a 12% acryl-
amide gel. The proteins were transferred to a nitrocellulose membrane
and incubated with a 1:2000 dilution of a polyclonal antibody that
recognizes both isoforms. The proteins were identi¢ed by chemolumi-
nescence as previously described [5].
2.5. Mobility shift assays
Gel retardation analysis was performed with recombinant or in
vitro translated proteins and an oligonucleotide corresponding to
the proximal GHF-1 binding site of the rat GH promoter (5P-
CCAGCCATGAATAAATGTATAAGGG-3P). For the binding as-
say, the proteins were incubated on ice for 15 min in a bu¡er (20
mM Tris-HCl (pH 7.5), 75 mM KCl, 1 mM dithiothreitol, 5 mg/ml
bovine serum albumin, 13% glycerol) containing 3 Wg Poly(dI-dC) and
then for 15^20 min at room temperature with approximately 50 000
cpm double-stranded oligonucleotide end-labeled with [32P]ATP, us-
ing T4-polynucleotide kinase. Each binding reaction contained the
same amount of extract or proteins which was obtained by adding
the appropriate amount of mock lysate or bacterial proteins. DNA^
protein complexes were resolved on 7.5% polyacrylamide gels in 0.5%
TBE bu¡er. The gels were then dried and autoradiographed at
370‡C.
3. Results and discussion
We have examined the ability of GHF-1 and its splice var-
iant GHF-2 to activate the rat GH promoter in pituitary and
non-pituitary cells. Fig. 1A shows the in£uence of increasing
amounts of GHF-1 and GHF-2 expression vectors on the
activity of the -530GH-CAT construct in Cos-7 cells. Basal
promoter activity was very low and GHF-1 enhanced this
activity in a dose-dependent manner. However, GHF-2 was
much less e¡ective in stimulating the GH promoter even when
high concentrations of GHF-2 plasmid were used. Fig. 1B
compares the e¡ect of transfection with the same amount of
expression vectors for GHF-1 and GHF-2 in Cos-7 and HeLa
cells. The degree of GHF-1 dependent induction was much
greater in HeLa than in Cos-7 cells, and in both the e¡ect of
GHF-2 was negligible in comparison with that produced by
GHF-1. The in£uence of both isoforms was also examined in
the -145GH-CAT construct. GHF-1 increased the activity of
-145GH-CAT by about 4- and 15-fold in Cos-7 and Hela
cells, respectively, whereas GHF-2 was practically ine¡ective.
There was the possibility that the GHF-2 isoform was not
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Fig. 1. A: Di¡erent potency of GHF-1 and GHF-2 on the activation of the GH promoter. Duplicate culture of Cos-7 cells were co-transfected
with 5 Wg of the -530GH-CAT construct and the indicated amounts of vectors expressing GHF-1 or GHF-2. CAT activity was determined 48
h after transfection. The data represent the mean þ S.D. of two independent experiments. B: In£uence of GHF-1 and GHF-2 on the expression
of the GH promoter in heterologous cells. The -530GH-CAT plasmid (right) and a construct containing a shorter fragment (-145GH-CAT)
(left) were transfected into Cos-7 and HeLa cells alone or in combination with 10 Wg of vectors expressing GHF-1 and/or GHF-2. CAT activity
was determined 48 h after transfection and represents the mean of 3 to 5 independent experiments. C: Dominant negative e¡ect of GHF-2 in
HeLa cells. Ten micrograms of a construct containing the rat prolactin promoter (-3000Prl-CAT) was transfected alone or with 10 Wg GHF-1,
10 Wg GHF-2 or both as indicated. The data represent the mean þ S.D. of CAT activity obtained from triplicate cultures. D: Detection by
Western blot analysis of GHF-1 and GHF-2 in transiently transfected cells. HeLa cells were transfected with 10 Wg of vectors expressing GHF-
1 (lane 4) or GHF-2 (lane 5), or with the same amount of an empty non-coding vector (lane 3). Transfection e⁄ciency determined by co-trans-
fection with a luciferase vector (CMV-luc) was similar in all cases. The cell extracts (150 Wg) were probed with a polyclonal antibody that rec-
ognizes both recombinant GHF-1 and GHF-2 (lanes 1 and 2). Lane 6 shows the immunoblot obtained using an extract from pituitary GH3
cells. The sizes of the proteins are indicated by arrows.
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present in the cells transfected with its expression vector or
that the factor was inactive in these cells. However, as shown
in Fig. 1C, GHF-2 is expressed in su⁄cient amounts in HeLa
cells to abolish the activation of the prolactin promoter by
GHF-1 as described [5]. To further analyze whether di¡eren-
ces in GHF-1 and GHF-2 levels could account for the de-
creased activity of GHF-2 on the GH promoter, we examined
the levels of both isoforms by Western blot in HeLa cells
transfected with equal amounts of expression vectors of
GHF-1 and GHF-2 under the same conditions as those shown
in panel B. Fig. 1D shows that the antibody used in the assay
recognizes both recombinant GHF-1 (lane 1) and GHF-2
(lane 2). Neither isoform was detected in HeLa cells trans-
fected with the empty expression vector (lane 3, RSV-0), but
GHF-1 (lane 4) and GHF-2 (lane 5) were detected in roughly
similar amounts in cells transfected with the corresponding
expression vectors. Lane 6 illustrates the results obtained in
pituitary cells in which GHF-1 is the predominant isoform [5].
These data con¢rm that the GH promoter can be signi¢-
cantly stimulated by expression of GHF-1 in cell types that
lack the endogenous protein. In contrast, we observe that
GHF-2 is markedly less e⁄cient than GHF-1. These results
di¡er from others which state that GHF-2 stimulates the GH
promoter in other non-pituitary cell lines [5,7], but correlate
with more recent data obtained in a de¢cient K-TSH cell line
in which GHF-2 also failed to stimulate this promoter [18].
These observations would suggest the existence of additional
cell-speci¢c factors required for e⁄cient activation by GHF-2.
The identity of the POU and homeobox domains of GHF-1
and GHF-2 suggested that they could bind similarly to DNA,
and binding of both isoforms to DNA has been previously
reported [5]. However, a careful examination by gel retarda-
tion analysis demonstrates a di¡erent binding potency of
GHF-1 and GHF-2. Fig. 2A shows binding of in vitro trans-
lated GHF-1 and GHF-2 to the GHF-1 binding site of the
GH promoter, and Fig. 2C shows that translation e⁄ciency of
the two isoforms was similar. Although the amounts of GHF-
1 and GHF-2 applied for the gel retardation assays were
identical, GHF-1 (lanes 2 to 4) produced a much stronger
retardation than GHF-2 (lanes 5 to 7) showing that the a⁄n-
ity of GHF-2 is markedly reduced. This lower a⁄nity was also
demonstrated by using recombinant GHF-1 and GHF-2. Pan-
el D in Fig. 2 shows Coomasie blue staining of the recombi-
nant preparations and panel B shows the retardation pro-
duced by increasing amounts of GHF-1 and GHF-2.
Although the concentration of GHF-2 used for the DNA
binding assays was similar to that of GHF-1, the later isoform
produced a much stronger retardation with the DNA ele-
ments. These di¡erences in binding a⁄nity must contribute
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Fig. 2. DNA binding of GHF-1 and GHF-2. A: Mobility shift assays with the proximal GHF-1 binding site of the rat GH promoter and ‘in
vitro’ translated GHF-1 and GHF-2. The 32P-labeled oligonucleotide was used for gel retardation with 1, 2 and 4 Wl of in vitro translated
GHF-1 (lanes 2^4) and GHF-2 (lanes 5^7). Lane 1 shows that 4 Wl of unprogrammed transcription^translation mixture did not produce retar-
dation. B: The oligonucleotide was incubated with increasing amounts (0.1 Wl, 0.25 Wl and 0.5 Wl) of recombinant GHF-1 (lanes 1^3) and
GHF-2 (lanes 4^6). C: The in vitro translated proteins used in panel A (1 Wl) were subjected to SDS-PAGE. The expected sizes for GHF-1 (33
kDa) and GHF-2 (36 kDa) are indicated by arrows. In panel D the Coomassie Blue staining of 12 Wl of the recombinant preparations of
GHF-1 and GHF-2 used in panel B is shown.
Fig. 3. GHF-1 but not GHF-2 cooperates with T3 and RA recep-
tors in regulating GH promoter activity in Cos-7 cells. The cells
were transfected with the -530GH-CAT construct in the absence (^)
or presence of 5 Wg of expression vectors for TR or RAR in combi-
nation with 1 Wg of RXR vector (TR/RXR and RAR/RXR, respec-
tively). The cells were also transfected with 10 Wg of GHF-1, GHF-
2, or both. Each transfection was split into di¡erent plates and
CAT activity was determined after 48 h in control cells (C) and in
cells incubated with 5 nM T3 or 1 mM RA.
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to the di¡erent transactivation potency of both splice variants.
On the other hand, GHF-1 binds as a homodimer [19,20], and
it can also heterodimerize with other proteins such as the
transcription factor Oct-1 [21] and most likely GHF-2 itself.
We have detected the existence of factors in Cos-7 cells that
produce a more e⁄cient GHF-1 binding (unpublished results).
GHF-2 could compete with GHF-1 for these proteins and/or
could form less active GHF-1/GHF-2 heterodimers.
A functional cooperation between the T3 receptors and
GHF-1 has been previously reported [22]. Induction of the
rat GH promoter by both isoforms of the pituitary factor in
the presence of transfected T3 and RA receptors was also
examined in Cos-7 cells (Fig. 3). Expression of TR/RXR
caused a ligand-independent increase of CAT activity (5- to
6-fold over control uninduced levels) even in the absence of
GHF-1. Interestingly, T3 did not activate the promoter in the
presence of TR/RXR unless GHF-1 was co-transfected. How-
ever, in cells transfected with the receptors plus GHF-1 incu-
bation with the hormone increased maximally (almost 15-fold
over control levels) the promoter activity. Fig. 3 also illus-
trates the in£uence of RAR/RXR. In the absence of GHF-
1, the retinoid receptors by themselves increased CAT activity
although with a lower potency than thyroid hormone recep-
tors. Co-transfection with GHF-1 further increased promoter
activity, and a clear synergistic e¡ect was observed when RA
was added to cells expressing both the receptors and GHF-1.
These results may be signi¢cant in vivo since it has been
reported that the two GHF-1 binding sites are necessary, but
not su⁄cient, for e⁄cient transcriptional activation of the rat
GH gene promoter in transgenic mice. The inclusion of addi-
tional sequences which contain the T3/RA response element
results in much higher levels of transgene expression suggest-
ing the existence of synergistic interactions between GHF-1
and this element [23]. On the other hand, the ¢nding that
GHF-1 is required for the ligand-dependent stimulation of
the GH promoter not only supports a role for synergism
with the nuclear receptors on GH gene expression, but also
contributes to explain the strict pituitary-speci¢c expression of
this gene, since only in pituitary cells where GHF-1 is ex-
pressed the potent stimulatory e¡ect of T3 and RA could be
observed.
In contrast to the results obtained with GHF-1, the combi-
nation of TR/RXR or RAR/RXR and GHF-2 exhibits no
synergistic e¡ect on the GH promoter, and this isoform was
ine¡ective even in the presence of the ligands. A clear dem-
onstration of the di¡erent transactivating properties of GHF-
1 and GHF-2 was obtained in pituitary GH4C1 cells. Fig. 4
shows that T3, RA and the combination of both increased the
activity of the GH promoter in GH4C1 cells. In these cells,
which already contain endogenous GHF-1 and nuclear recep-
tors, over-expression of this factor produced a 4- to 5-fold
increase in CAT basal levels and markedly enhanced the re-
sponse to T3 and RA. These results con¢rm the existence of
functional cooperation between the receptors for both ligands
and GHF-1. In contrast with the e¡ect of GHF-1, transfec-
tion with an expression vector for GHF-2 did not increase the
response to T3 and RA, but rather almost totally blocked the
response to both ligands. The speci¢city of this inhibition is
shown by the ¢nding that GHF-2 did not decrease basal GH
promoter activity. It should be noted that GHF-2 did not
signi¢cantly block the e¡ect of T3 or RA in Cos-7 cells ex-
pressing GHF-1. It is possible that a di¡erent relative concen-
tration of both GHF-1 and GHF-2 could be involved in the
di¡erences in the behaviour of both isoforms in pituitary and
non-pituitary cell lines. That the ratio GHF-1/GHF-2 is im-
portant in determining the response to T3 and RA was shown
by the ¢nding that when GHF-1 and GHF-2 were transfected
together, the response to both ligands in GH4C1 cells was
partially restored (Fig. 4).
Alternative splicing has been shown to generate diversity in
the expression of di¡erent transcription factors with di¡erent
transcriptional e¡ects. Our results show a synergism of GHF-
1 with thyroid hormone and RA receptors. However, the de-
creased DNA binding a⁄nity in GHF-2 substantially de-
creases its transcriptional activity and prevents the coopera-
tion with the nuclear receptors. The lower binding and activity
of GHF-2, together with the fact that GHF-1 is the predom-
inant form expressed in both normal pituitaries and in pitui-
tary cell lines [5], suggests that the larger splice variant does
not play a dominant regulatory role in GH gene expression.
However, a signi¢cant role for GHF-2 on the GH promoter
under physiological or pathological conditions in which this
isoform could be preferentially synthesized cannot be dis-
missed. On the other hand, GHF-2 could speci¢cally regulate
other, still unidenti¢ed, pituitary-speci¢c genes.
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